Clinical stage cell therapy company Chimeric Therapeutics (ASX:CHM) has updated investors to confirm that all patients dosed in the first cohort in the phase one CLTX CAR-T cell clinical trial have now advanced beyond the 28-day follow up period without experiencing dose-limiting toxicities.
The company said the achievement of this safety milestone for all patients in cohort one will enable the trial to advance to the second dosing level.
The CLTX CAR T cell clinical trial is taking place at City of Hope, a cancer research and treatment centre in the US.
“We are very pleased to have reached this significant milestone with our CLTX CAR T cell therapy as it enables us to advance the development of this important therapy for patients with progressive or recurrent Glioblastoma,” said Jennifer Chow, Chimeric Therapeutics chief operating officer.
“We look forward to further progressing the development of CLTX CAR T and to providing updates as we seek to bring the promise of cell therapy to life for more patients with cancer.”